Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 9/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 12/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009343 | 0.86 | JAK1 (0.48) | JAK1JAK3CHEK1ROCK2RPS6KA5 | |
| SCHEMBL14493878 | 0.85 | CCNT1 (0.50) | JAK1JAK3CHEK1ROCK2RPS6KA5 | |
| SCHEMBL30009302 | 0.82 | JAK1 (0.52) | JAK1JAK3CHEK1ROCK2RPS6KA5 | |
| SCHEMBL14420789 | 0.81 | JAK1 (0.50) | JAK1 | |
| SCHEMBL10125393 | 0.80 | JAK1 (0.64) | JAK1JAK3CHEK1ROCK2RPS6KA5 | |
| SCHEMBL3602461 | 0.80 | JAK1 (0.65) | JAK1 | |
| SCHEMBL14493885 | 0.80 | JAK1 (0.57) | JAK1JAK3 | |
| SCHEMBL20918915 | 0.77 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30355773 | 0.77 | JAK1 (1.00) | JAK1 | |
| SCHEMBL29430994 | 0.77 | JAK1 (0.47) | JAK1BTKJAK3CHEK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885BTK 236/4885JAK3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.